Form 4: Sage Therapeutics Executive Disposes Equity Following Supernus Merger Completion

Gregory L. Shiferman, SVP and General Counsel of Sage Therapeutics, disposed of common stock, restricted stock units, and stock options as part of the company's merger with Supernus Pharmaceuticals, receiving cash and contingent value rights.

Summary

• Gregory L. Shiferman, Senior Vice President, General Counsel, and Secretary of Sage Therapeutics, Inc., disposed of his beneficial ownership in the company following its merger with Supernus Pharmaceuticals, Inc.
• The merger became effective on July 31, 2025, as per the Agreement and Plan of Merger dated June 13, 2025.
• Each outstanding common share was converted into $8.50 per share in cash (the "Closing Amount") plus one contingent value right (CVR).
• Each CVR represents the right to receive up to an additional $3.50 per share in cash upon the satisfaction of specified milestones, as detailed in a Form 8-K filed on June 16, 2025.
• Restricted Stock Units (RSUs) held by Mr. Shiferman were fully vested and converted into a cash payment equal to the Closing Amount ($8.50) multiplied by the number of shares subject to the RSU, plus one CVR per RSU.
• Stock options with an exercise price less than the Closing Amount ($8.50) were fully vested and converted into a cash payment equal to the difference between the Closing Amount and the exercise price, multiplied by the total number of shares subject to the option, plus one CVR per share subject to the option.
• Stock options with an exercise price greater than or equal to the Closing Amount ($8.50) were cancelled without consideration.

Sentiment

Score: 7

Explanation: The filing reports the successful completion of a merger, resulting in the conversion of equity holdings into cash and CVRs for the reporting person. This provides liquidity and potential upside, indicating a generally positive outcome for the individual involved, consistent with the terms of a previously announced acquisition.

Positives

• Reporting person received cash consideration of $8.50 per share for common stock and RSUs, providing immediate liquidity.
• Reporting person received cash consideration for in-the-money stock options ($6.05 and $6.97 exercise prices) based on the difference between the $8.50 closing amount and the exercise price.
• Reporting person received contingent value rights (CVRs) for each share, RSU, and in-the-money option, offering potential additional cash payments of up to $3.50 per CVR upon milestone achievement.

Negatives

• Reporting person no longer holds direct beneficial ownership in Sage Therapeutics, Inc. common stock or derivative securities.
• The value of the contingent value rights (CVRs) is contingent on future milestones, introducing uncertainty regarding the full potential payout of $3.50 per CVR.

Risks

• The contingent value rights (CVRs) are subject to the satisfaction of specified milestones, meaning the full potential payout of up to $3.50 per CVR is not guaranteed and depends on future events.

Future Outlook

The future outlook for the contingent value rights (CVRs) is dependent on the satisfaction of specified milestones, which could result in additional cash payments of up to $3.50 per CVR. Details regarding these milestones are available in the Form 8-K filed on June 16, 2025.

Industry Context

This filing reflects the completion of a merger between Sage Therapeutics, a biopharmaceutical company, and Supernus Pharmaceuticals, Inc. Such mergers are common in the pharmaceutical and biotechnology sectors as companies seek to consolidate assets, expand pipelines, and achieve economies of scale. The use of contingent value rights (CVRs) is a common mechanism in biotech acquisitions to bridge valuation gaps and share future development risks or successes.

Comparison to Industry Standards

• This Form 4 details a specific insider transaction related to a merger, rather than operational or financial performance, making direct comparisons to industry-wide financial benchmarks or competitor results not applicable.
• The structure of the merger consideration, including a cash component and contingent value rights, is a common practice in pharmaceutical and biotechnology acquisitions, similar to deals seen with companies like BioMarin Pharmaceutical Inc. or Acadia Pharmaceuticals Inc. in their respective acquisition histories, where CVRs have been used to incentivize future performance or mitigate risk related to pipeline assets.

Stakeholder Impact

• Shareholders (Reporting Person): The reporting person's equity holdings were converted into cash and CVRs, providing a defined exit and potential future payments.
• Former Sage Therapeutics Shareholders: All former shareholders received $8.50 per share in cash plus one CVR, concluding their ownership in Sage Therapeutics.
• Supernus Pharmaceuticals, Inc. Shareholders: The merger's completion means Supernus Pharmaceuticals, Inc. has successfully acquired Sage Therapeutics, potentially impacting Supernus's future financial performance and strategic direction.

Next Steps

• Potential future cash payments to CVR holders upon the satisfaction of specified milestones, as detailed in the Form 8-K filed on June 16, 2025.

Key Dates

Keywords

Sage Therapeutics, Supernus Pharmaceuticals, Merger, Acquisition, Form 4, SEC Filing, Insider Transaction, Equity Disposition, Contingent Value Right, CVR, Stock Option, Restricted Stock Unit, Corporate Action, Biotechnology, Pharmaceuticals